Company Filing History:
Years Active: 2006
Title: The Innovations of Nicholas A. Giorgio
Introduction
Nicholas A. Giorgio is a notable inventor based in New York, NY (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for cancer treatment and other medical applications.
Latest Patents
Nicholas A. Giorgio holds a patent for a humanized anti-EGF receptor monoclonal antibody. This patent describes a nucleic acid that encodes a humanized antibody or fragment thereof, which binds to the human EGF receptor. The monoclonal antibody 225 serves as the complementary determining region (CDR) donor. This innovation represents a critical advancement in targeted therapies.
Career Highlights
Giorgio is associated with Imclone Systems, Inc., a company known for its focus on developing innovative cancer therapies. His work at Imclone has positioned him as a key player in the biotechnology sector. With a patent portfolio that includes 1 patent, he continues to contribute to advancements in medical science.
Collaborations
Throughout his career, Nicholas has collaborated with esteemed colleagues such as Neil I. Goldstein and Steven Tarran Jones. These partnerships have fostered a collaborative environment that enhances research and development efforts.
Conclusion
Nicholas A. Giorgio's contributions to biotechnology, particularly through his patent on humanized monoclonal antibodies, highlight his role as an influential inventor. His work continues to impact the field and offers promise for future medical advancements.